hotspot -WSS

hotspot

author：entertainment 2025-09-29 22:46:41 - browse：68734

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： A protest over insulin prices is seen as a fight for life

focus

knowledge

WSS

Covid misinformation case heads to Supreme Court

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

New Ultima Genomics DNA sequencer can read genome for $100

Congressmen charge Covid hearing ‘could have been an email’

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

The CDC's new social media misinformation war

explore

hotspot

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Some dementia cases could be undiagnosed liver disease

Medical records are filled with copy

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Medicare details structure of new drug price negotiation program

Apple Vision Pro: A first look at health apps on the new VR headset

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The CDC's new social media misinformation war

Medicare details structure of new drug price negotiation program

A single Democrat is willing to weaken Medicare negotiation power

knowledge

Some dementia cases could be undiagnosed liver disease

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Juul spent big to court Black leaders to promote its e

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Biden administration opens offers in Medicare drug price negotiations

Medicare drug price negotiation’s day in court

focus

focus

knowledge

entertainment